Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 60, Number 9, May 13, 2003
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, M. D.
Right arrow Articles by Buchan, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, M. D.
Right arrow Articles by Buchan, A. M.
Related Collections
Right arrow All Immunology
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction

Neurology 2003;60:1525-1527
© 2003 American Academy of Neurology
Brief Communications

Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke

M. D. Hill, MD FRCPC, T. Lye, BA, H. Moss, BA, P. A. Barber, MB ChB, MRCP(UK), A. M. Demchuk, MD FRCPC, N. J. Newcommon, RN MSc, T. L. Green, RN MA, C. Kenney, RN, A. Cole–Haskayne, RN and A. M. Buchan, BM FRCP

From the Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Foothills Hospital, Alberta, Canada.

Address correspondence and reprint requests to Dr. Michael D. Hill, Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Foothills Hospital, 1403 29 St. NW, Rm.1242A, Calgary, Alberta, Canada T2N 2T9; e-mail: michael.hill{at}calgaryhealthregion.ca

One hundred seventy-six consecutive patients treated with IV tissue plasminogen activator (tPA) for acute ischemic stroke were examined prospectively, and orolingual angioedema was found in nine (5.1%; 95% CI 2.3 to 9.5). The reaction was typically mild, transient, and contralateral to the ischemic hemisphere. Risk of angioedema was associated with angiotensin-converting enzyme inhibitors (relative risk [RR] 13.6; 95% CI 3.0 to 62.7) and signs on initial CT of ischemia in the insular and frontal cortex (RR 9.1; 95% CI 1.4 to 30.0).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.